Drugs / IBR733
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06234904 | Mar 2024 → Jul 2027 expected | acute myeloid leukemia | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBR733 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06234904 ↗ |
| Modality | Cell therapy | “IBR733 cell injection” NCT06234904 ↗ |
| Route | Intravenous | “intravenous infusion” NCT06234904 ↗ |